Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plasmodium falciparum sporozoites are the infectious stage of the *Plasmodium falciparum* parasite, responsible for causing malaria. In a therapeutic context, they are utilized as a vaccine or for controlled human malaria infection (CHMI) studies. The sporozoites are typically aseptic, purified, cryopreserved, and metabolically active, but rendered non-replicating through radiation attenuation (PfRAS) or chemoattenuation (PfSPZ-CVac) to prevent full-blown infection while still eliciting a protective immune response. This approach aims to induce cellular and humoral immunity to confer protection against *P. falciparum* infection, serving as a vaccine candidate for malaria prevention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Plasmodium falciparum sporozoites.